Tecartus Eiropas Savienība - igauņu - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lümfoom, mantle-cell - antineoplastilised ained - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Dimethyl fumarate Neuraxpharm Eiropas Savienība - igauņu - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Pemetrexed Baxter Eiropas Savienība - igauņu - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Imjudo Eiropas Savienība - igauņu - EMA (European Medicines Agency)

imjudo

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastilised ained - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Tremelimumab AstraZeneca Eiropas Savienība - igauņu - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Arexvy Eiropas Savienība - igauņu - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoorsed süntsüütilised viirusinfektsioonid - vaktsiinid - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

CEFEPIME HOSPIRA süste-/infusioonilahuse pulber Igaunija - igauņu - Ravimiamet

cefepime hospira süste-/infusioonilahuse pulber

hospira uk limited - tsefepiim - süste-/infusioonilahuse pulber - 2g 20ml 5tk; 2g 20ml 10tk; 2g 20ml 1tk

CEFEPIME HOSPIRA süste-/infusioonilahuse pulber Igaunija - igauņu - Ravimiamet

cefepime hospira süste-/infusioonilahuse pulber

hospira uk limited - tsefepiim - süste-/infusioonilahuse pulber - 1g 20ml 5tk

VANCOMYCIN HOSPIRA infusioonilahuse kontsentraadi pulber Igaunija - igauņu - Ravimiamet

vancomycin hospira infusioonilahuse kontsentraadi pulber

hospira uk limited - vankomütsiin - infusioonilahuse kontsentraadi pulber - 1000mg 10ml 1tk

VANCOMYCIN HOSPIRA infusioonilahuse kontsentraadi pulber Igaunija - igauņu - Ravimiamet

vancomycin hospira infusioonilahuse kontsentraadi pulber

hospira uk limited - vankomütsiin - infusioonilahuse kontsentraadi pulber - 500mg 10ml 1tk